Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Etelcalcetide
Drug ID BADD_D02514
Description Etelcalcetide is a calcimimetic drug for the treatment of secondary hyperparathyroidism in patients undergoing hemodialysis. Etelcalcetide was approved (trade name Parsabiv) for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis in February, 2017.
Indications and Usage Etelcalcetide is a calcium-sensing receptor agonist indicated for: Secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis.
Marketing Status approved; investigational
ATC Code H05BX04
DrugBank ID DB12865
KEGG ID D10676
MeSH ID C583569
PubChem ID 71511839
TTD Drug ID D07RYI
NDC Product Code 55463-0030; 55513-741; 55513-740; 52076-6227; 55513-742
UNII 60ME133FJB
Synonyms etelcalcetide hydrochloride | velcalcetide | etelcalcetide | KAI-4169 | Parsabiv | AMG-416 | AMG 416
Chemical Information
Molecular Formula C38H73N21O10S2
CAS Registry Number 1262780-97-1
SMILES CC(C(=O)NC(CCCN=C(N)N)C(=O)N)NC(=O)C(CCCN=C(N)N)NC(=O)C(CCCN=C(N)N)NC(=O)C(CCCN= C(N)N)NC(=O)C(C)NC(=O)C(CSSCC(C(=O)O)N)NC(=O)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Feeling abnormal08.01.09.0140.026719%Not Available
Feeling hot08.01.09.0090.005625%Not Available
Flatulence07.01.04.0020.004986%
Gastrooesophageal reflux disease07.02.02.0030.004986%
Gastrointestinal disorder07.11.01.0010.042955%Not Available
Gastrointestinal haemorrhage24.07.02.009; 07.12.02.0010.012145%Not Available
Haematochezia07.12.02.003; 24.07.02.0120.001278%Not Available
Hypercalcaemia14.04.01.003; 05.04.01.0020.006903%
Hyperkalaemia14.05.03.0010.002557%
Hypervolaemia02.05.04.019; 14.05.06.0030.001278%Not Available
Hypoaesthesia23.03.03.081; 17.02.06.0230.020199%Not Available
Hypocalcaemia14.04.01.0040.110199%
Interstitial lung disease22.01.02.003; 10.02.01.0330.001918%Not Available
Intestinal perforation07.04.06.0020.004474%Not Available
Lethargy19.04.04.004; 17.02.04.003; 08.01.01.0080.013679%
Malaise08.01.01.0030.033367%
Migraine24.03.05.003; 17.14.02.0010.012145%Not Available
Muscle spasms15.05.03.0040.049730%
Muscle twitching15.05.03.0050.022372%Not Available
Muscular weakness15.05.06.001; 17.05.03.0050.013679%
Musculoskeletal pain15.03.04.0070.004347%
Myalgia15.05.02.0010.041932%
Myocardial infarction24.04.04.009; 02.02.02.0070.005753%
Myocardial ischaemia24.04.04.010; 02.02.02.0080.003196%Not Available
Nausea07.01.07.0010.187415%
Nightmare19.02.03.0030.008693%Not Available
Palpitations02.11.04.0120.027358%
Paraesthesia23.03.03.094; 17.02.06.0050.039759%
Parathyroid tumour benign16.37.02.002; 05.04.03.0030.001278%Not Available
Peripheral ischaemia24.04.03.0020.001278%
The 2th Page    First    Pre   2 3 4    Next   Last    Total 4 Pages